Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma

Clinical Nuclear Medicine

Volumn 37, Issue 2, 2012, Pages 121-127

  Grabellus, Florian ^a   Nagarajah, James ^a   Bockisch, Andreas ^a   Schmid, Kurt Werner ^a   Sheu, Sien Yi ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

GLUT1; PET CT; poorly differentiated thyroid cancer; thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; IODINE; IODINE 124; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POORLY DIFFERENTIATED THYROID CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; KI-67 ANTIGEN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; THYROID NEOPLASMS;

EID: 84855799446     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182393599     Document Type: Article

References (39)

1. Heston TF, Wahl RL. Molecular imaging in thyroid cancer. Cancer Imaging. 2010;10:1-7
2. Rivera M, Ghossein RA, Schoder H, et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography- positive thyroid carcinoma. Cancer. 2008;113:48-56 (Pubitemid 351976385)
3. Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131- iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-1472 (Pubitemid 26321624)
4. Wang W, Macapinlac H, Larson SM, et al.18F-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302
5. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324: 1029-1033
6. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387 (Pubitemid 34072519)
7. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979-2985 (Pubitemid 23335044)
8. Goldman NA, Katz EB, Glenn AS, et al. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol. 2006;19:1429-1436 (Pubitemid 44624161)
9. Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with F-18-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926-932 (Pubitemid 38500750)
10. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202: 654-662 (Pubitemid 40175840)
11. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res. 2002;35:9-26 (Pubitemid 34661867)
12. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392-1398 (Pubitemid 46874072)
13. Haber RS, Weiser KR, Pritsker A, et al. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid. 1997;7:363-367
14. Schonberger J, Ruschoff J, Grimm D, et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002;12:747-754
15. Yasuda M, Ogane N, Hayashi H, et al. Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep. 2005;14:1499-1504
16. Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92:1144-1150 (Pubitemid 32861663)
17. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983;52:1849-1855 (Pubitemid 14228153)
18. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): World Health classification of tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004
19. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31: 1256-1264 (Pubitemid 47207131)
20. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue-in German. Pathologe. 1987;8: 138-140
21. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379 (Pubitemid 30643379)
22. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology. 2004;230:879-885 (Pubitemid 38252890)
23. Beyer T, Antoch G, Blodgett T, et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588-596 (Pubitemid 36559838)
24. Freudenberg LS, Jentzen W, Gorges R, et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin. 2007;46:121-128 (Pubitemid 47356534)
25. Garber K. Energy deregulation: licensing tumors to grow. Science. 2006;312: 1158-1159
26. Yeluri S, Madhok B, Prasad KR, et al. Cancers craving for sugar: an opportunity for clinical exploitation. J Cancer Res Clin Oncol. 2009;135:867-877
27. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292-306
28. Arora N, Scognamiglio T, Zhu B, et al. Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg. 2008;32:1237-1246
29. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322 (Pubitemid 30054364)
30. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med. 2000;27:1778-1785
31. Ravazoula P, Batistatou A, Aletra C, et al. Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol. 2003;24:544-546 (Pubitemid 37462578)
32. Younes M, Brown RW, Mody DR, et al. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15:2895-2898 (Pubitemid 26095119)
33. Bogsrud TV, Karantanis D, Nathan MA, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid. 2008;18:713-719 (Pubitemid 352009926)
34. Pace L, Nicolai E, Klain M, et al. Diagnostic value of FDG PET/CT imaging. Q J Nucl Med Mol Imaging. 2009;53:503-512
35. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med. 2007;32:690-695 (Pubitemid 47294862)
36. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616-624 (Pubitemid 46768462)
37. Diehl M, Graichen S, Menzel C, et al. F-18 FDG PET in insular thyroid cancer. Clin Nucl Med. 2003;28:728-731 (Pubitemid 38295196)
38. Poisson T, Deandreis D, Leboulleux S, et al. (18)F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:2277-2258
39. Wang W, Larson SM, Fazzari M, et al. Prognostic value of 18F fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113 (Pubitemid 32269357)